Santhera Pharmaceuticals Holding AG (XSWX:SANN) PS Ratio: 2.58 (As of Jul. 03, 2026) — 21% Below Median


XSWX:SANN Santhera Pharmaceuticals Holding AG XSWX:SANN
39 GF Score
Price CHF15.20
GF Value CHF23.24
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Santhera Pharmaceuticals Holding AG PS Ratio?

Santhera Pharmaceuticals Holding AG XSWX:SANN -0.26% 39 PS Ratio is 2.58 as of Jul. 03, 2026, which is 21% below its 10-year median of 3.26. GuruFocus rates XSWX:SANN with a GF Score™ of 39/100 and a GF Value™ of CHF23.24 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 933 Biotechnology companies, Santhera Pharmaceuticals Holding AG ranks better than 80.28% on this metric.

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Santhera Pharmaceuticals Holding AG's share price is CHF15.20. Santhera Pharmaceuticals Holding AG's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was CHF5.89. Hence, Santhera Pharmaceuticals Holding AG's PS Ratio for today is 2.58.

The historical rank and industry rank for Santhera Pharmaceuticals Holding AG's PS Ratio or its related term are showing as below:

XSWX:SANN' s PS Ratio Range Over the Past 10 Years
Min: 0.38   Med: 3.26   Max: 97.27
Current: 2.57

During the past 13 years, Santhera Pharmaceuticals Holding AG's highest PS Ratio was 97.27. The lowest was 0.38. And the median was 3.26.

XSWX:SANN's PS Ratio is ranked better than
80.28% of 933 companies
in the Biotechnology industry
Industry Median: 9.64 vs XSWX:SANN: 2.57

Santhera Pharmaceuticals Holding AG's Revenue per Sharefor the six months ended in Dec. 2025 was CHF4.01. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was CHF5.89.

During the past 12 months, the average Revenue per Share Growth Rate of Santhera Pharmaceuticals Holding AG was 72.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was 69.10% per year.

During the past 13 years, Santhera Pharmaceuticals Holding AG's highest 3-Year average Revenue per Share Growth Rate was 288.30% per year. The lowest was -73.90% per year. And the median was 12.80% per year.

Back to Basics: PS Ratio


Santhera Pharmaceuticals Holding AG  (XSWX:SANN) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Santhera Pharmaceuticals Holding AG PS Ratio Related Terms


Santhera Pharmaceuticals Holding AG PS Ratio Historical Data

* Premium members only.

The historical data trend for Santhera Pharmaceuticals Holding AG's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santhera Pharmaceuticals Holding AG PS Ratio Chart

Santhera Pharmaceuticals Holding AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 11.26 1.04 4.02 2.12

Santhera Pharmaceuticals Holding AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.04 0.00 4.02 0.00 2.12

XSWX:SANN vs VRTX, REGN, ALNY: PS Ratio Comparison

For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santhera Pharmaceuticals Holding AG PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's PS Ratio distribution charts can be found below:

* The bar in red indicates where Santhera Pharmaceuticals Holding AG's PS Ratio falls into.


XSWX:SANN
39GF Score
Santhera Pharmaceuticals Holding AG XSWX:SANN
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Santhera Pharmaceuticals Holding AG PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Santhera Pharmaceuticals Holding AG's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=15.20/5.892
=2.58

Santhera Pharmaceuticals Holding AG's Share Price of today is CHF15.20.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Santhera Pharmaceuticals Holding AG's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was CHF5.89.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.

Frequently Asked Questions Learn more about PS Ratio →
What does a PS Ratio of 2.58 mean?
Santhera Pharmaceuticals Holding AG (XSWX:SANN) has a PS Ratio of 2.58 as of Jul. 03, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. This is 21% below median its historical median of 3.26. Over the past decade, Santhera Pharmaceuticals Holding AG's PS Ratio has ranged from 0.38 to 97.27. According to the industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #184 out of 933 companies in the Biotechnology industry, placing it in the top 19.7%.
Is Santhera Pharmaceuticals Holding AG's PS Ratio too high?
Santhera Pharmaceuticals Holding AG's current PS Ratio of 2.58 is 21% below median its 10-year median of 3.26. Over the past 10 years, this metric has ranged from a low of 0.38 to a high of 97.27. The Biotechnology industry median PS Ratio is 9.64. Santhera Pharmaceuticals Holding AG's value of 2.58 is 73.2% below this industry median. Based on the distribution chart, Santhera Pharmaceuticals Holding AG ranks #184 out of 933 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Santhera Pharmaceuticals Holding AG has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Santhera Pharmaceuticals Holding AG's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #184 out of 933 companies for PS Ratio. This places Santhera Pharmaceuticals Holding AG in the top 20% of its industry — outperforming the majority of peers. The industry median PS Ratio is 9.64. Santhera Pharmaceuticals Holding AG's value of 2.58 is 73.2% below this benchmark. Historically, Santhera Pharmaceuticals Holding AG's own PS Ratio has ranged from 0.38 to 97.27 over the past decade. While the company's 10-year median is 3.26 vs. the industry median of 9.64, Santhera Pharmaceuticals Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.64, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Santhera Pharmaceuticals Holding AG's current PS Ratio of 2.58 is 73.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. For the Biotechnology industry, the median PS Ratio is 9.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Santhera Pharmaceuticals Holding AG's current PS Ratio is 2.58, which is 21% below median its own 10-year median of 3.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santhera Pharmaceuticals Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG (XSWX:SANN) is currently considered Possible Value Trap. The stock's GF Value™ is CHF23.24, compared to a current price of CHF15.20 — trading 34.6% below its estimated fair value. The current PS Ratio is 2.58, which is 21% below median its 10-year median of 3.26 and 73.2% below the Biotechnology industry median of 9.64. Santhera Pharmaceuticals Holding AG's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Santhera Pharmaceuticals Holding AG (XSWX:SANN), the current PS Ratio is 2.58 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santhera Pharmaceuticals Holding AG (XSWX:SANN) Overvalued in 2026?

Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG stock appears to be undervalued. The current stock price of CHF15.20 is trading 34.6% below its estimated GF Value™ of CHF23.24. GuruFocus considers Santhera Pharmaceuticals Holding AG to be Possible Value Trap.

Key valuation signals for XSWX:SANN:

  • PS Ratio: 2.58 (21% below median its 10-year median of 3.26)
  • GF Value™: CHF23.24 vs. price of CHF15.20 (34.6% below fair value)
  • GF Score™: 39/100 with 6 warning signs
  • Industry Position: 73.2% below the Biotechnology median (#184 of 933)

No single metric tells the full story. See the XSWX:SANN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Santhera Pharmaceuticals Holding AG Business Description

Address Hohenrainstrasse 24, Pratteln, CHE, 4133
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
39GF Score

Get the complete analysis for XSWX:SANN

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF15.20
Price
CHF23.24
GF Value